دورية أكاديمية
أعرض في EDS

Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1.

التفاصيل البيبلوغرافية
العنوان: Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1.
المؤلفون: Tayshetye P; Department of Hematology-Oncology, Allegheny Health Network, Pittsburgh, PA 15212, USA., Friday AJ; Department of Medical Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA., Omstead AN; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA., Verma T; Department of Pathology and Laboratory Medicine, Allegheny Health Network, Pittsburgh, PA 15212, USA., Miller S; Department of Pathology and Laboratory Medicine, Allegheny Health Network, Pittsburgh, PA 15212, USA., Zheng P; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA., Jani P; Hematology and Oncology, Northeast Cancer Centre, Sudbury, ON P3E 5J1, Canada., Zaidi A; Esophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA., Finley G; Department of Medical Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
المصدر: Cancers [Cancers (Basel)] 2022 Dec 31; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 31.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: In locally advanced rectal cancer treatment, neoadjuvant concurrent chemoradiation therapy (cCRT) is the standard of care. The tumor microenvironment (TME) is a complex entity comprising of tumor cells, immune cells and surrounding stroma and is closely associated with tumor growth and survival, response to antitumor therapies and also resistance to treatment. We aimed to assess the change in biomarkers associated with TME following standard neoadjuvant cCRT in rectal cancer.
Methods: We accessed archival tissue from rectal cancer patients treated with neoadjuvant cCRT at Allegheny Health Network (AHN) facilities over the past 14 years. Pre-treatment and post-treatment biopsies were assayed for PD-L1, CD8+ T-cells, CXCL9, TIM-3, IDO-1, IFN-G, IL17RE, LAG-3, and OX40 in 41 patients.
Results: We found statistically significant upregulation in multiple biomarkers namely CD8, IL17RE, LAG3 and OX40 post neoadjuvant cCRT and a trend towards upregulation, although not statistically significant, in biomarkers PD-L1, CXCL9, TIM-3, IDO-1 and IFN-G expression.
Conclusions: This provides a glimpse into the TME before and after neoadjuvant cCRT. We suggest that the biomarkers noted to be upregulated could be used for designing appropriate clinical trials and development of therapeutic targeted drug therapy in an effort to achieve better response to neoadjuvant therapy, increasing clinical and pathological complete response rates and improved overall outcomes.
References: Immunol Rev. 2008 Apr;222:206-21. (PMID: 18364004)
Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. (PMID: 29500275)
Br J Cancer. 2011 Jun 28;105(1):93-103. (PMID: 21629244)
Gene Ther. 2014 Sep;21(9):794-801. (PMID: 24919418)
J Hematol Oncol. 2018 Mar 15;11(1):39. (PMID: 29544515)
CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
Mediators Inflamm. 2014;2014:623759. (PMID: 25110397)
Lancet Oncol. 2010 Sep;11(9):835-44. (PMID: 20692872)
Br J Cancer. 2013 Aug 20;109(4):1013-22. (PMID: 23868006)
Clin Cancer Res. 2016 May 15;22(10):2329-34. (PMID: 27016309)
N Engl J Med. 2012 Mar 8;366(10):925-31. (PMID: 22397654)
Immunity. 2008 Apr;28(4):454-67. (PMID: 18400188)
Cancer Res. 2017 Dec 15;77(24):6795-6811. (PMID: 29247038)
N Engl J Med. 2022 Jun 23;386(25):2363-2376. (PMID: 35660797)
Aging (Albany NY). 2020 Jan 8;12(1):502-517. (PMID: 31913856)
Cancer Med. 2016 Nov;5(11):3246-3259. (PMID: 27726306)
Signal Transduct Target Ther. 2020 Aug 25;5(1):166. (PMID: 32843638)
JAMA Oncol. 2018 Jun 14;4(6):e180071. (PMID: 29566109)
Surg Oncol Clin N Am. 2010 Oct;19(4):829-45. (PMID: 20883957)
Science. 2006 Sep 29;313(5795):1960-4. (PMID: 17008531)
Cancer Sci. 2016 Sep;107(9):1193-7. (PMID: 27297395)
J Hematol Oncol. 2018 Aug 2;11(1):100. (PMID: 30068361)
Ann N Y Acad Sci. 2009 Dec;1182:69-79. (PMID: 20074276)
Front Oncol. 2014 Nov 28;4:325. (PMID: 25506582)
Annu Rev Immunol. 2016 May 20;34:539-73. (PMID: 26927206)
Oncotarget. 2016 Dec 6;7(49):81281-81291. (PMID: 27793030)
Mol Immunol. 2017 Mar;83:13-22. (PMID: 28092803)
J Clin Oncol. 2005 Dec 1;23(34):8688-96. (PMID: 16246976)
Cell Commun Signal. 2020 Apr 7;18(1):59. (PMID: 32264958)
Immunity. 2016 May 17;44(5):989-1004. (PMID: 27192565)
Clin Sci (Lond). 2015 Oct;129(7):601-72. (PMID: 26186743)
Dis Markers. 2014;2014:792183. (PMID: 25609852)
J Clin Oncol. 2009 Dec 10;27(35):5944-51. (PMID: 19858404)
Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Ann Surg. 2011 Jul;254(1):97-102. (PMID: 21494121)
Br J Surg. 2012 Jul;99(7):918-28. (PMID: 22362002)
Blood. 2009 Jul 16;114(3):555-63. (PMID: 19465693)
فهرسة مساهمة: Keywords: biomarker; chemoradiation; immunotherapy; neoadjuvant; rectal cancer; tumor microenvironment
تواريخ الأحداث: Date Created: 20230108 Latest Revision: 20230111
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9818440
DOI: 10.3390/cancers15010276
PMID: 36612271
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15010276